<DOC>
	<DOCNO>NCT00191516</DOCNO>
	<brief_summary>A single arm , open-label , phase 3 multicenter study evaluate effectiveness tolerability atomoxetine ( give daily , target dose 1.2 mg/kg/day ) , perceive patient , parent physician , impact quality sleep child ( age 6 11 year ) Attention-Deficit/Hyperactivity Disorder treat outpatient Germany . An 8-week treatment phase follow 16-week extension period .</brief_summary>
	<brief_title>An Open-Label Study Atomoxetine Children With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient least 6 year age reach 12th birthday Diagnosis ADHD Normal intelligence Weigh le 20 kg 60 kg study entry Other relevant psychiatric diagnosis Are serious suicidal risk determine investigator Have history severe allergy Alcohol drug abuse within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>